Scholarlink

<p>Fluorescent probes operating within the near-infrared second window (NIR-II, 1000–1700&#xa0;nm), characterized by high tissue transparency and minimal tissue-induced photon scattering/absorption, have been widely applied for early-stage disease diagnosis. However, the capability of NIR-II emitters for deep-tissue imaging is limited by relatively low brightness, which hinders the acquisition of images at low excitation intensity and administration dose. Herein, we introduce a novel in situ strategy to fabricate ultrabright Ag<sub>2</sub>S nanoparticles (Ag<sub>2</sub>S super NPs) <i>via</i> aftertreatment of chemically synthesized Ag<sub>2</sub>S NPs, where a protective shell grown by a 2-minutes rapid microwave irradiation. This shell effectively reduces the surface and structural defects, resulting in a 25-fold promotion of the quantum yield and 38-times increment of the fluorescence lifetime. The nontoxic PEGylated Ag<sub>2</sub>S super NPs enable<i> in vivo</i> deep-tissue imaging under low excitation laser (1 mW/cm<sup>2</sup>) and administration dose (0.5&#xa0;mg/kg). Furthermore, after the modification with targeting peptide, Ag<sub>2</sub>S super NPs exhibit outstanding imaging performance by achieving an over 90% intensity promotion compared to commercial Ag<sub>2</sub>S NPs for targeted inflammation imaging in gastritis and myocarditis models. These results present an effective, cost-effective and rapid enhancement approach to obtain ultrabright NIR-II imaging contrast agent, thereby advancing their potential for pre-clinical diagnosis imaging applications. </p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rapid in situ microwave-assisted fabrication of ultrabright near-infrared probe for low-dose in vivo inflammatory imaging

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月26日

查看全文
  • Deqiang Ruan,
  • Chong Hu,
  • Zeping Yang,
  • Fan Zhang,
  • Bin Guo,
  • Yimin Lei,
  • Daniel Jaque,
  • Yingli Shen,
  • Fu Wang

摘要

Fluorescent probes operating within the near-infrared second window (NIR-II, 1000–1700 nm), characterized by high tissue transparency and minimal tissue-induced photon scattering/absorption, have been widely applied for early-stage disease diagnosis. However, the capability of NIR-II emitters for deep-tissue imaging is limited by relatively low brightness, which hinders the acquisition of images at low excitation intensity and administration dose. Herein, we introduce a novel in situ strategy to fabricate ultrabright Ag2S nanoparticles (Ag2S super NPs) via aftertreatment of chemically synthesized Ag2S NPs, where a protective shell grown by a 2-minutes rapid microwave irradiation. This shell effectively reduces the surface and structural defects, resulting in a 25-fold promotion of the quantum yield and 38-times increment of the fluorescence lifetime. The nontoxic PEGylated Ag2S super NPs enable in vivo deep-tissue imaging under low excitation laser (1 mW/cm2) and administration dose (0.5 mg/kg). Furthermore, after the modification with targeting peptide, Ag2S super NPs exhibit outstanding imaging performance by achieving an over 90% intensity promotion compared to commercial Ag2S NPs for targeted inflammation imaging in gastritis and myocarditis models. These results present an effective, cost-effective and rapid enhancement approach to obtain ultrabright NIR-II imaging contrast agent, thereby advancing their potential for pre-clinical diagnosis imaging applications.

Graphical Abstract